
    
      This pilot study will be conducted in subjects with metastatic prostate cancer in order to
      define whether inclusion of immune regulation agents such as CDX-1127 augments immune
      responses to SBRT-treated primary tumors or metastases, and whether inclusion of CDX-1127 in
      the treatment regimen results in immune responses in untreated metastases.
    
  